Dexycu

DRUG5 trials

Sponsors

The Eye Institute of West Florida, EyePoint Pharmaceuticals, Inc., Ocumension Therapeutics (Shanghai) Co., Ltd

Conditions

CataractInflammation

Phase 3

A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery (2)

WithdrawnNCT05550363

EyePoint Pharmaceuticals, Inc.Cataract

Start: 2022-09-30End: 2023-09-30Updated: 2024-04-03

A Study to Evaluate the Efficacy and Safety of DEXYCU® for the Treatment of Ocular Pain Associated With Cataract Surgery

WithdrawnNCT05550350

EyePoint Pharmaceuticals, Inc.Cataract

Start: 2022-09-30End: 2023-09-30Updated: 2025-08-11

Study of Dexycu in Treating Intraocular Inflammation

CompletedNCT06429306

Ocumension Therapeutics (Shanghai) Co., LtdCataract, Inflammation

Start: 2022-08-22End: 2024-04-09Updated: 2024-08-26

Phase 4

A Prospective Study of the Efficacy of Intracameral Dexamethasone (Dexycu™) Compared to Standard of Care Treatment for Post-Cataract Surgical Pain and Anterior Chamber Inflammation

CompletedNCT04781335

The Eye Institute of West FloridaCataract

Start: 2020-02-20End: 2022-12-22Updated: 2025-02-25

A Real-world Study of DEXYCU in the Treatment of Inflammation After Cataract Surgery

CompletedNCT06497699

Ocumension Therapeutics (Shanghai) Co., LtdCataract, Inflammation

Start: 2021-10-28End: 2023-12-14Updated: 2025-09-03